Biologics will continue to drive market growth despite leading brands Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab) losing patent protection in most of the major markets over the forecast period. <br />Complete report is available @ http://www.rnrmarketresearch.com/systemic-psoriasis-therapeutics-in-major-developed-markets-to-2020-continued-uptake-of-biologics-and-novel-pipeline-drugs-to-drive-growth-market-report.html .
